University of Maryland, Baltimore
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).
University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.
University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.
Top-decile sponsor footprint
University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
560 total, page 2 of 12
Acute Normovolemic Hemodilution on Urine Neutrophil Gelatinase-associated Lipocalin Levels
NCT05349292
Barriers to Vegetarian Diets
NCT07075653
The ROle of Compression StocKings in Heart Failure Patients
NCT06350695
Working Memory and Physical Exercise Training in Patients With Mild Cognitive Impairment
NCT05948930
Testing the Pain Clinical Practice Guideline
NCT05858996
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
NCT05615844
Sickle Cell Children's Exercise Study (SuCCESs)
NCT06074198
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
NCT06103201
Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention
NCT06002685
CT TAVR Abdomen Study
NCT05758701
Measuring Acute Drug Demand in Humans
NCT05829655
Comparing Direct vs Indirect Methods for Cascade Screening
NCT05348564
Recovery Among Older Adults Following Mild TBI
NCT07569354
Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy
NCT05756426
Change in MAPSE During Treatment of Sepsis
NCT05634733
Ocular Blood Flow Imaging for Glaucoma Assessment
NCT05726058
Divided or Single Exposure (DOSE) Study
NCT05459402
Prebiotic Treatment in People With Schizophrenia
NCT05527210
Targeting Emotion Dysregulation to Reduce Suicide in People With Psychosis
NCT05440214
Subscap Reverse Shoulder Arthroplasty
NCT05344898
TERPS Trial for de Novo Oligometastic Prostate Cancer
NCT05223803
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
NCT05450965
Retinal Blood Flow and Autoregulation
NCT05344274
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
NCT04946721
Pharmacogenetics of Response to GLP1R Agonists
NCT05071898
Cardiopulmonary Bypass Induced Red Blood Cell Lysis
NCT05189262
Glucose Variability and Cognition in Prediabetes
NCT04201600
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
NCT05027919
Neural Correlates of Hypoalgesia Driven by Observation
NCT03897998
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT04234386
Hybrid Robot+FES Stroke Rehabilitation
NCT04550728
Trial of Therapeutic Hypothermia in Patients With ARDS
NCT04545424
Real Time Vital Sign Assessment to Predict Neurological Decline After Traumatic Brain Injury
NCT05084352
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
NCT04699773
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
NCT04698564
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04486755
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
NCT04772456
LITT Followed by Hypofractionated RT for Recurrent Gliomas
NCT04181684
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
NCT04050280
Sensory-Motor Rehabilitation Post Stroke
NCT02369770
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
NCT03652428
GammaPod Registry and Quality of Life Nomogram
NCT03562273
CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera
NCT03705585
Robot Aided Rehabilitation - Intervention
NCT02359253
Robot Aided Rehabilitation - Multi-joint Evaluations
NCT02359812
The Effects of Fluoxetine and/or DHEA
NCT03228732
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
NCT03201094
Differing Levels of Hypoglycemia
NCT02445781
The CREST-2 Registry
NCT02240862
The HOPE Study: Characterizing Patients With Hepatitis B and C
NCT02995252
What is open in the University of Maryland, Baltimore pipeline
103 recruiting of 560 indexed (18% open); 332 completed (59%).
Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (14 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Maryland, Baltimore: open-pipeline peers nationwide
Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 560 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Abramson Cancer Center at Penn Medicine · 18% recruiting · 402 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this University of Maryland, Baltimore page
560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.
- 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets.Report a data error.